Compare Amneal Pharmaceuticals Inc. Class A Common Stock (AMRX) vs Eaton Corporation plc (ETN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amneal Pharmaceuticals Inc. Class A Common Stock vs Eaton Corporation plc — how do they compare? Amneal Pharmaceuticals Inc. Class A Common Stock trades at $19.27 (market cap $6.59B), while Eaton Corporation plc trades at $401.09 (market cap $158.80B). The key difference: Eaton Corporation plc is far larger — about 24.1× Amneal Pharmaceuticals Inc. Class A Common Stock's market cap, and Eaton Corporation plc pays a 1.08% dividend while Amneal Pharmaceuticals Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Amneal Pharmaceuticals Inc. Class A Common Stock for 7 Days and Eaton Corporation plc for 33 Days on average.
| AMRX | ETN | |
|---|---|---|
Market Cap | $6.59B | $158.80B |
Volume | 3,962,792 | 3,207,896 |
Sector | Health | Industrials |
52-Week High | $20.50 | $459.96 |
52-Week Low | $9.78 | $315.82 |
Typical Hold Time | 7 Days | 33 Days |
Enterprise Value | $9.25B | $179.43B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMRX trades at $19.57, down 2.3% today but maintains strong momentum with three consecutive quarterly earnings beats. The stock shows bullish technical signals with positive moving averages and analyst consensus of $23.20 price target. Recent FDA approval of Lanreotide Injection and completion of Kashiv BioSciences acquisition position the company for biosimilar growth, while revenue guidance has been raised for 2026.
The outlook remains positive with improving profitability and strategic expansion into biosimilars, though execution risks and Rytary product erosion present challenges. With 65% analyst buy ratings and institutional accumulation, AMRX offers growth potential but requires monitoring of integration success and competitive pressures in the pharmaceutical sector.
Eaton Corporation (ETN) trades at $408.85, down 4.54% today, with strong fundamentals including 12.75% net income margin and 19.71% ROE. The stock shows bearish technical signals but maintains positive earnings momentum with three consecutive quarterly beats. Recent acquisitions in data center and utility markets support long-term growth prospects amid strong AI infrastructure demand.
Outlook remains positive with 70% analyst buy ratings and $502.38 consensus target, though technical weakness and valuation premiums pose near-term risks. The company's strategic positioning in data center power and aerospace provides durable growth catalysts, while high P/E of 41.63 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amneal Pharmaceuticals Inc. Class A Common Stock
Amneal Pharmaceuticals develops, manufactures, and distributes generic and specialty medicines. Its businesses include affordable medicines, specialty products, and the AvKARE distribution business.
Read more on AMRX →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
